Cargando…

1582. Dolutegravir/Rilpivirine STR Switch Study in Persons with HIV-1 and Chronic Kidney Disease: 48-week Assessment of Viral Suppression, Treatment Adherence and Quality of Life

BACKGROUND: Single tablet regimens (STRs) are widely utilized in HIV treatment in the Western world largely because they improve convenience of oral regimens and eliminate differential adherence. US Blacks are disproportionately impacted by HIV, and are also disproportionately affected by chronic ki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwakwa, Helena, Stokes, Tawanaha, Gebreselassie, Millen, Maslankowski, Lisa, Chernak, Esther
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677703/ http://dx.doi.org/10.1093/ofid/ofad500.1417

Ejemplares similares

1582. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year
por: Sension, Michael G, et al.
Publicado: (2022)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016)

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health
por: McComsey, Grace A., et al.
Publicado: (2018)

Efficacy of switching to dolutegravir plus rilpivirine, the small-tablet regimen, in patients with dysphagia: two case reports
por: Suzuki, Takefumi, et al.
Publicado: (2017)

Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi‐centre 48‐week efficacy and safety study in Thailand
por: Phongsamart, Wanatpreeya, et al.
Publicado: (2022)

2541. Steady-state PK of Fixed Dose Dolutegravir+Rilpivirine in Hemodialysis
por: Gupta, Samir K, et al.
Publicado: (2023)

Romancero historiado (Alcalá, 1582)
por: Rodríguez, Lucas, fl. 1579-1585
Publicado: (1967)

2484. Patient Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 148 Results from the Sword-1 and Sword-2 Studies
por: Oglesby, Alan, et al.
Publicado: (2019)

2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen
por: Ward, Douglas, et al.
Publicado: (2019)

Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
por: Troya, Jesús, et al.
Publicado: (2022)

Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2
por: Llibre, Josep M., et al.
Publicado: (2022)

884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies
por: Teichner, Paula, et al.
Publicado: (2019)

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
por: Murray, Miranda, et al.
Publicado: (2020)

The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet
por: Mehta, Rashmi, et al.
Publicado: (2020)

Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study
por: Palacios, Rosario, et al.
Publicado: (2018)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks
por: Jörimann, Lisa, et al.
Publicado: (2023)

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2022)

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
por: Troya, Jesús, et al.
Publicado: (2016)

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
por: Rizzardini, Giuliano, et al.
Publicado: (2020)

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
por: Raffi, François, et al.
Publicado: (2015)

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials
por: van Wyk, Jean, et al.
Publicado: (2020)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
por: Troya, Jesús, et al.
Publicado: (2017)

833. Efficacy and Safety of Long-Acting Cabotegravir + Rilpivirine in Participants with HIV/HCV Co-infection: ATLAS-2M 48-Week Results
por: D’Amico, Ronald, et al.
Publicado: (2021)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort
por: Teira, Ramón, et al.
Publicado: (2022)

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection
por: Mehta, Rashmi, et al.
Publicado: (2018)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

538 A Retrospective Study to Evaluate the Safety of Switching Antiretroviral Therapy (ART) to Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) STR in Virologically Suppressed HIV-Infected Patients
por: Monczor, Ana, et al.
Publicado: (2014)

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
por: Riccardi, Niccolò, et al.
Publicado: (2019)

PReS13-SPK-1582: Activity and damage - we have to measure them
por: Feldman, BM
Publicado: (2013)

Weight gain in patients starting Dolutegravir-based ART according to baseline CD4 count after 48 weeks of follow up
por: Cardoso-Neto, Érico C., et al.
Publicado: (2023)

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
por: Mulindwa, Frank, et al.
Publicado: (2023)

2483. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States
por: Pierone, Gerald, et al.
Publicado: (2019)

Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2022)

2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies
por: Patel, Parul, et al.
Publicado: (2019)

Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups
por: Rawlings, M Keith, et al.
Publicado: (2022)

Bacillus firmus Strain I-1582, a Nematode Antagonist by Itself and Through the Plant
por: Ghahremani, Zahra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5mlqff4b08jlm97jfqeidjv8qr